Levofolino Rūgštis Medac (Levoleucovorin Disodium)

Levoleucovorin disodium supplies a reduced folate that bypasses the dihydrofolate reductase blockade created by methotrexate. Once inside cells, it is converted to tetrahydrofolate derivatives that donate one‑carbon units for purine and pyrimidine synthesis, thereby restoring DNA replication and normal cell function.

The dose of levoleucovorin disodium is individualized by the prescribing clinician based on the indication, patient weight, renal function and the methotrexate regimen being rescued. Healthcare professionals determine the appropriate amount and infusion rate; patients should not adjust the dose on their own.

Safety data for levoleucovorin disodium in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Levofolino Rūgštis Medac delivers levoleucovorin disodium, a reduced folate analogue similar in function to folinic acid (leucovorin). Both bypass methotrexate‑induced dihydrofolate reductase inhibition, but formulation differences (e.g., concentration, stability) may influence handling and dosing preferences in specific clinical protocols.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and follow aseptic techniques for preparation and intravenous administration.

Levofolino Rūgštis Medac is given by intravenous infusion. The solution is typically diluted with a compatible IV fluid and administered over a period defined by the treating physician, often immediately after or shortly before high‑dose methotrexate infusion, to ensure optimal rescue effect.

Serious adverse events, although rare, include anaphylactic or severe hypersensitivity reactions, acute renal failure, severe electrolyte imbalances, pulmonary toxicity, and significant hepatic dysfunction. Prompt recognition and medical intervention are essential if any of these reactions occur.

Patients with known hypersensitivity to levoleucovorin disodium or any component of the formulation should avoid the product. Caution is also advised in individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those receiving concurrent high‑dose folate antagonists without appropriate monitoring.